SCHEMBL274846

SCHEMBL274846

O=C(Nc1ccc(Cl)cc1C(=O)N/N=C/c1cccc(F)c1)c1cnc2ccccc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 1/20 0.53
SLC34A1 Q06495 1/20 0.53
SLC34A3 Q8N130 1/20 0.53
SLC20A1 Q8WUM9 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
RAB9A P51151 5/20 0.53
NPC1 O15118 4/20 0.53
TDP1 Q9NUW8 2/20 0.53
FAAH O00519 3/20 0.52
MAPT P10636 3/20 0.50
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
GUSB P08236 1/20 0.50
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
GAA P10253 2/20 0.47
USP2 O75604 1/20 0.47
THRB P10828 1/20 0.47
HPGD P15428 1/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266630 1.00 SLC34A2 (0.53) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL266482 0.87 NPC1 (0.58) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL273711 0.87 NPC1 (0.58) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL268292 0.86 NPC1 (0.53) SMN1; SMN2RAB9ANPC1FAAHMAPT
SCHEMBL274849 0.86 NPC1 (0.53) SMN1; SMN2RAB9ANPC1FAAHMAPT
SCHEMBL268921 0.84 AURKA (0.44) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL274464 0.84 AURKA (0.44) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL264530 0.80 SLC34A2 (0.61) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL264529 0.80 SLC34A2 (0.61) SLC34A2SLC34A1SLC34A3SLC20A1SMN1; SMN2
SCHEMBL273866 0.78 NPC1 (0.54) SMN1; SMN2RAB9ANPC1TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885SLC34A1 1/4885SLC34A3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.